Literature DB >> 29864110

Hematologic Malignancies Associated With Mediastinal Germ Cell Tumors: 10 Years' Experience at Thailand's National Pediatric Tertiary Referral Center.

Panjarat Sowithayasakul1, Phakatip Sinlapamongkolkul2, Jitsupa Treetipsatit3, Nassawee Vathana4, Nattee Narkbunnam4, Kleebsabai Sanpakit4, Jassada Buaboonnam4.   

Abstract

Mediastinal germ cell tumor (MGCT), which accounts for 1% to 3% of extragonadal germ cell tumors, has unique manifestations; it is associated with several types of hematologic malignancy, particularly myeloid neoplasm. The aim of this study was to report the 10-year incidence, clinical characteristics, and outcomes of MGCT at Thailand's national pediatric tertiary referral center. This retrospective study included patients diagnosed with MGCT at the Department of Pediatrics, Siriraj Hospital during 2005 to 2014. Eight patients (all male) were diagnosed with MGCT. Five of 8 patients were found to have hematologic abnormalities. Three patients were diagnosed with acute myeloid leukemia (AML) (one patient with M1, another having M7, and the other with M0). Another patient had mixed MGCT with mediastinal myeloid sarcoma (MMS). The other patient had malignancy-associated hemophagocytic lymphohistiocytosis syndrome (M-HLH). Isochromosome 12p was detected in 3 patients (AML [2], mixed MGCT/MMS [1]). Four of 5 patients with hematologic abnormalities died of hematologic abnormalities or treatment complication (AML [3], M-HLH [1]). One patient with mixed MGCT/MMS survived with chemotherapy. All patients with AML and MMS were nonseminomatous MGCT and the onset of myeloid malignancies were within 1 year after the diagnosis of MGCT. Associated hematologic malignancies should be suspected in MGCT with abnormal blood count or hematologic symptoms. Isochromosome 12p was the most common cytogenetic finding in MGCT-associated myeloid malignancies patients. Those with nonseminomatous MGCT should have their blood count carefully monitored especially during the first year after the diagnosis of MGCT. Better treatment alternatives for MGCT with associated hematologic malignancies are warranted to ameliorate adverse outcomes.

Entities:  

Mesh:

Year:  2018        PMID: 29864110     DOI: 10.1097/MPH.0000000000001233

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience.

Authors:  Hiroshi Yaegashi; Takahiro Nohara; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Tomoyuki Makino; Kaname Yamashita; Koushiro Ohtsubo; Hiroko Ikeda; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2022-05-03

2.  Malignant histiocytosis associated with mediastinal germ cell tumor: A case report.

Authors:  Pei-Yi Yang; Xiao-Li Ma; Wen Zhao; Li-Bing Fu; Rui Zhang; Qi Zeng; Hong Qin; Tong Yu; Yan Su
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

3.  Giant malignant sacrococcygeal germ cell tumor in a newborn: A rare case report.

Authors:  Carmela Brillantino; Maria Elena Errico; Rocco Minelli; Giovanni Gaglione; Pietro Pirisi; Antonio Rossi; Biagio Francesco Menna; Marika Santarsiere; Mariateresa Rumolo; Eugenio Rossi
Journal:  Radiol Case Rep       Date:  2022-05-07

4.  Establishment and validation of an individualized nomogram for survival prediction of primary mediastinal germ cell tumors based on the SEER database.

Authors:  Longzhou Qi; Jiajun Han; Yifan Shi; Ruizhi Wu; Bin Li; Weiqiang Shi; Shaomu Chen
Journal:  Ann Transl Med       Date:  2022-09

5.  Acute Mast Cell Leukemia Preceded by Malignant Mediastinal Germ Cell Tumor: A Case Report and Literature Review.

Authors:  Huafang Wang; Yuan Chen; Huijun Lin; Wanmao Ni; Qiaolei Zhang; Jianping Lan; Lai Jin
Journal:  Cancer Manag Res       Date:  2022-05-23       Impact factor: 3.602

Review 6.  Pediatric mediastinal germ cell tumors.

Authors:  Aanchal Kakkar; Kavneet Kaur; Ajay Verma
Journal:  Mediastinum       Date:  2019-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.